Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
01 2020
Historique:
received: 06 03 2019
accepted: 18 07 2019
pubmed: 1 8 2019
medline: 9 6 2020
entrez: 1 8 2019
Statut: ppublish

Résumé

Kabuki syndrome (KS) (OMIM 147920 and 300867) is a rare genetic disorder characterized by specific facial features, intellectual disability, and various malformations. Immunopathological manifestations seem prevalent and increase the morbimortality. To assess the frequency and severity of the manifestations, we measured the prevalence of immunopathological manifestations as well as genotype-phenotype correlations in KS individuals from a registry. Data were for 177 KS individuals with KDM6A or KMT2D pathogenic variants. Questionnaires to clinicians were used to assess the presence of immunodeficiency and autoimmune diseases both on a clinical and biological basis. Overall, 44.1% (78/177) and 58.2% (46/79) of KS individuals exhibited infection susceptibility and hypogammaglobulinemia, respectively; 13.6% (24/177) had autoimmune disease (AID; 25.6% [11/43] in adults), 5.6% (10/177) with ≥2 AID manifestations. The most frequent AID manifestations were immune thrombocytopenic purpura (7.3% [13/177]) and autoimmune hemolytic anemia (4.0% [7/177]). Among nonhematological manifestations, vitiligo was frequent. Immune thrombocytopenic purpura was frequent with missense versus other types of variants (p = 0.027). The high prevalence of immunopathological manifestations in KS demonstrates the importance of systematic screening and efficient preventive management of these treatable and sometimes life-threatening conditions.

Identifiants

pubmed: 31363182
doi: 10.1038/s41436-019-0623-x
pii: S1098-3600(21)01131-X
doi:

Substances chimiques

DNA-Binding Proteins 0
KMT2D protein, human 0
Neoplasm Proteins 0
Histone Demethylases EC 1.14.11.-
KDM6A protein, human EC 1.14.11.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-188

Références

Niikawa N, Matsuura N, Fukushima Y, et al. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99:565–569.
doi: 10.1016/S0022-3476(81)80255-7
Ng SB, Bigham AW, Buckingham KJ, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010;42:790–793.
doi: 10.1038/ng.646
Lederer D, Grisart B, Digilio MC, et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet. 2012;90:119–124.
doi: 10.1016/j.ajhg.2011.11.021
Hu D, Gao X, Morgan MA, et al. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol. 2013;33:4745–4754.
doi: 10.1128/MCB.01181-13
Miyake N, Koshimizu E, Okamoto N, et al. MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am J Med Genet. 2013;161:2234–2243.
doi: 10.1002/ajmg.a.36072
Banka S, Lederer D, Benoit V, et al. Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2). Clin Genet. 2015;87:252–258.
doi: 10.1111/cge.12363
Hoffman JD, Ciprero KL, Sullivan KE, et al. Immune abnormalities are a frequent manifestation of Kabuki syndrome. Am J Med Genet A. 2005;135A:278–281.
doi: 10.1002/ajmg.a.30722
Lin J-L, Lee W-I, Huang J-L, et al. Immunologic assessment and KMT2D mutation detection in Kabuki syndrome: immunologic and genetic KMT2D analysis in Kabuki syndrome. Clin Gen. 2015;88:255–260.
doi: 10.1111/cge.12484
De Dios JAA, Javaid AA, Ballesteros E, Metersky ML. An 18-year-old woman with Kabuki syndrome, immunoglobulin deficiency and granulomatous lymphocytic interstitial lung disease. Conn Med. 2012;76:15–18.
pubmed: 22372173
Ming JE, Russell KL, McDonald-McGinn DM, Zackai EH. Autoimmune disorders in Kabuki syndrome. Am J Med Genet. 2005;132A:260–262.
doi: 10.1002/ajmg.a.30332
Almécija AC, Pérez V, Baro M, et al. Atypical autoimmune hematologic disorders in a patient with Kabuki syndrome. J Pediatr Hematol Oncol. 2019;41:e114–e115.
doi: 10.1097/MPH.0000000000001182
Zannolli R, Buoni S, Macucci F, et al. Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G. Brain Dev. 2007;29:373–376.
doi: 10.1016/j.braindev.2006.11.004
Gürbüz F, Yüreğir ÖÖ, Ceylaner S, et al. Coexistence of Kabuki syndrome and autoimmune thyroiditis. J Clin Res Pediatr Endocrinol. 2016;8:105.
doi: 10.4274/jcrpe.2686
Fujishiro M, Ogihara T, Tsukuda K, et al. A case showing an association between type 1 diabetes mellitus and Kabuki syndrome. Diabetes Res Clin Pract. 2003;60:25–31.
doi: 10.1016/S0168-8227(02)00276-0
Ho J, Fox D, Innes AM, et al. Kabuki syndrome and Crohn disease in a child with familial hypocalciuric hypercalcemia. J Pediatr Endocrinol Metab. 2010;23:975–979.
doi: 10.1515/jpem.2010.156
Nishizaki N, Fujinaga S, Hirano D, et al. Membranoproliferative glomerulonephritis type 3 associated with Kabuki syndrome. Clin Nephrol. 2014;81:369–373.
doi: 10.5414/CN107464
Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190–197.
doi: 10.1006/clim.1999.4799
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393.
doi: 10.1182/blood-2008-07-162503
Börgershausen N, Gatinois V, Riehmer V, et al. Mutation update for Kabuki syndrome genes KMT2D and KDM6A and further delineation of X‐linked Kabuki syndrome subtype 2. Hum Mutat. 2016;37:847–864.
doi: 10.1002/humu.23026
Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978–1980.
doi: 10.1093/bioinformatics/bty897
Lee MG, Villa R, Trojer P, et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science. 2007;318:447–450.
doi: 10.1126/science.1149042
Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 2011;25:661.
doi: 10.1101/gad.2015411
Lindsley AW, Saal HM, Burrow TA, et al. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. J Allergy Clin Immunol. 2016;137:179–187.
doi: 10.1016/j.jaci.2015.06.002
Borchert GM, Holton NW, Edwards KA, et al. Histone H2A and H2B are monoubiquitinated at AID-targeted loci. PLoS ONE. 2010;5:e11641.
doi: 10.1371/journal.pone.0011641
Wei G, Wei L, Zhu J, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity. 2009;30:155.
doi: 10.1016/j.immuni.2008.12.009
Stagi S, Gulino AV, Lapi E, Rigante D. Epigenetic control of the immune system: a lesson from Kabuki syndrome. Immunol Res. 2016;64:345–359.
doi: 10.1007/s12026-015-8707-4
Westh L, Mogensen TH, Dalgaard LS, et al. Identification and characterization of a nationwide Danish adult common variable immunodeficiency cohort. Scand J Immunol. 2017;85:450–461.
doi: 10.1111/sji.12551
Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33:197–207.
doi: 10.1016/j.jaut.2009.09.008
Moulis G, Palmaro A, Montastruc J-L, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124:3308–3315.
doi: 10.1182/blood-2014-05-578336
Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer. 2017;64:e26389.
doi: 10.1002/pbc.26389
Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96:655.
doi: 10.3324/haematol.2010.036053
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51:1206–1212.
doi: 10.1111/j.1365-4632.2011.05377.x
Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS ONE. 2016;11:e0163806.
doi: 10.1371/journal.pone.0163806
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223–243.
doi: 10.1006/clin.1997.4412
Warnatz K, Voll RE. Pathogenesis of autoimmunity in common variable immunodeficiency. Front Immunol. 2012;3:210.
doi: 10.3389/fimmu.2012.00210
Mahlaoui N, Warnatz K, Jones A, et al. Advances in the care of primary immunodeficiencies (PIDs): from birth to adulthood. J Clin Immunol. 2017;37:452–460.
doi: 10.1007/s10875-017-0401-y
Hannibal MC, Buckingham KJ, Ng SB, et al. Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. Am J Med Genet A. 2011;155A:1511–1516.
doi: 10.1002/ajmg.a.34074
Li Y, Bögershausen N, Alanay Y, et al. A mutation screen in patients with Kabuki syndrome. Hum Genet. 2011;130:715–724.
doi: 10.1007/s00439-011-1004-y
Makrythanasis P, van Bon BW, Steehouwer M, et al. MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype–phenotype study. Clin Genet. 2013;84:539–545.
doi: 10.1111/cge.12081
Micale L, Augello B, Fusco C, et al. Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients. Orphanet J Rare Dis. 2011;6:38.
doi: 10.1186/1750-1172-6-38

Auteurs

Henri Margot (H)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.

Guilaine Boursier (G)

Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.
INSERM U1183, Université de Montpellier, Montpellier, France.

Claire Duflos (C)

Département d'Information Médicale, CHU Montpellier, Montpellier, France.

Elodie Sanchez (E)

Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.
INSERM U1183, Université de Montpellier, Montpellier, France.

Jeanne Amiel (J)

Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Jean-Christophe Andrau (JC)

Institut de Génétique Moléculaire de Montpellier (IGMM), Univ Montpellier, Montpellier, France.

Stéphanie Arpin (S)

Service de génétique, CHU de Tours, UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.

Elise Brischoux-Boucher (E)

Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France.

Odile Boute (O)

Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France.

Lydie Burglen (L)

Centre de référence des malformations et maladies congénitales du cervelet, département de génétique et embryologie médicale, APHP, GHUEP, Hôpital Trousseau, Paris, France.

Charlotte Caille (C)

Service de génétique médicale, CHU de Brest, Brest, France.

Yline Capri (Y)

Service de génétique médicale, AP-HP Robert-Debré, Paris, France.

Patrick Collignon (P)

Service de génétique médicale, CHI de Toulon, Toulon, France.

Solène Conrad (S)

Service de génétique médicale, CHU de Nantes, Nantes, France.

Valérie Cormier-Daire (V)

Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Geoffroy Delplancq (G)

Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France.

Klaus Dieterich (K)

Service de génétique médicale, CHU de Grenoble, Grenoble, France.

Hélène Dollfus (H)

Service de génétique médicale, CHU de Strasbourg, Strasbourg, France.

Mélanie Fradin (M)

Service de génétique clinique, CHU de Rennes, Univ. Rennes, Institute of Genetics and Development of Rennes (IGDR) UMR6290 CNRS, Rennes, France.

Laurence Faivre (L)

Service de génétique médicale et centre de référence Anomalies du Développement et Syndromes Malformatifs, CHU de Dijon, Dijon, France.

Helder Fernandes (H)

Service d'onco hématologie pédiatrique, CHU de Bordeaux, Bordeaux, France.
Centre de référence des cytopénies auto-immunes de l'enfant, CHU de Bordeaux, Bordeaux, France.
INSERM CICP, Université de Bordeaux, Bordeaux, France.

Christine Francannet (C)

Service de génétique médicale, CHU de Clemont-Ferrand, Clermont-Ferrand, France.

Vincent Gatinois (V)

Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France.
INSERM U1183, Université de Montpellier, Montpellier, France.

Marion Gerard (M)

Service de génétique médicale, CHU de Caen, Caen, France.

Alice Goldenberg (A)

Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

Jamal Ghoumid (J)

Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France.

Sarah Grotto (S)

Service de génétique médicale, AP-HP Robert-Debré, Paris, France.

Anne-Marie Guerrot (AM)

Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

Agnès Guichet (A)

Service de génétique médicale, CHU d'Angers, Angers, France.

Bertrand Isidor (B)

Service de génétique médicale, CHU de Nantes, Nantes, France.

Marie-Line Jacquemont (ML)

Service de génétique médicale, CHU de la Reunion, Saint-Pierre, France.
Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.

Sophie Julia (S)

Service de génétique médicale, CHU de Toulouse, Toulouse, France.

Philippe Khau Van Kien (P)

Service de génétique médicale, CHU de Nîmes, Nîmes, France.

Marine Legendre (M)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.

K H Le Quan Sang (KH)

Institut Imagine, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Bruno Leheup (B)

Service de génétique médicale, CHU de Nancy, Nancy, France.

Stanislas Lyonnet (S)

Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Virginie Magry (V)

Service de génétique médicale, CHU de Clemont-Ferrand, Clermont-Ferrand, France.

Sylvie Manouvrier (S)

Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France.

Dominique Martin (D)

Service de génétique médicale, CH du Mans, Le Mans, France.

Godelieve Morel (G)

Service de génétique médicale, CHU de Nice, Nice, France.

Arnold Munnich (A)

Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Sophie Naudion (S)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.

Sylvie Odent (S)

Service de génétique clinique, CHU de Rennes, Univ. Rennes, Institute of Genetics and Development of Rennes (IGDR) UMR6290 CNRS, Rennes, France.

Laurence Perrin (L)

Service de génétique médicale, AP-HP Robert-Debré, Paris, France.

Florence Petit (F)

Centre de référence maladies rares pour les anomalies du développement Nord-Ouest, Clinique de Génétique médicale, CHU de Lille et EA7364, Université de Lille, Lille, France.

Nicole Philip (N)

Service de génétique médicale, CHU de Marseille, Marseille, France.

Marlène Rio (M)

Fédération de Génétique et Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP et INSERM UMR1163, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

Julie Robbe (J)

Service de génétique médicale, CHU de Marseille, Marseille, France.

Massimiliano Rossi (M)

Service de génétique médicale, CHU de Lyon, Lyon, France.

Elisabeth Sarrazin (E)

Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.

Annick Toutain (A)

Service de génétique, CHU de Tours, UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.

Julien Van Gils (J)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.
INSERM U1211, Université de Bordeaux, Bordeaux, France.

Gabriella Vera (G)

Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, Rouen, France.

Alain Verloes (A)

Service de génétique médicale, AP-HP Robert-Debré, Paris, France.

Sacha Weber (S)

Service de génétique médicale, CHU de Caen, Caen, France.

Sandra Whalen (S)

Service de génétique médicale, AP-HP Pitié Salpétrière, Paris, France.

Damien Sanlaville (D)

Service de génétique médicale, CHU de Lyon, Lyon, France.

Didier Lacombe (D)

Service de génétique médicale, CHU de Bordeaux, Bordeaux, France.
Centre de Référence Anomalies du développement et Syndromes malformatifs du Sud-Ouest Occitanie Réunion, Saint-Pierre, France.
INSERM U1211, Université de Bordeaux, Bordeaux, France.

Nathalie Aladjidi (N)

Service d'onco hématologie pédiatrique, CHU de Bordeaux, Bordeaux, France.
Centre de référence des cytopénies auto-immunes de l'enfant, CHU de Bordeaux, Bordeaux, France.
INSERM CICP, Université de Bordeaux, Bordeaux, France.

David Geneviève (D)

Département de génétique médicale, Maladies rares et médecine personnalisée, CHU de Montpellier, Montpellier, France. d-genevieve@chu-montpellier.fr.
INSERM U1183, Université de Montpellier, Montpellier, France. d-genevieve@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH